NEW YORK, Dec. 3, 2018 /PRNewswire/ -- Frontier Pharma: Schizophrenia - Diverse First-in-Class Pipeline Shows Promise for Treatment of Negative and Cognitive SymptomsRead the full report: https://www.reportlinker.com/p05436785
SummarySchizophrenia is a severe chronic mental disorder affecting a person's mental, emotional and physical wellbeing. Patients appear out of touch with reality, preventing them from functioning at school, at work, in relationships and in society. Schizophrenia affects approximately 1% of the global population and is associated with a sizeable economic burden, estimated at between 0.02% and 1.65% of the global gross domestic product.In the 1960s, the antipsychotic drug Chlorpromazine entered the market for the treatment of schizophrenia, spurring the development of first-generation or 'typical' antipsychotics. Despite being effective, the exact mechanisms of action of antipsychotics are largely unknown. Both Chlorpomazine and Clozapine are dopamine-2 (D2) receptor antagonists, which are effective in treating the positive symptoms of schizophrenia, including psychosis, but also come with a plethora of side effects such as abnormal movements and hyperprolactinemia.The schizophrenia pipeline is relatively small, given the large patient population and well-defined unmet needs, with a total of 160 products in active development. This is indicative of a low level of R&D funding and investment, most likely due to a poor understanding of the underlying mechanisms of the disease, which acts as a strong barrier to the development of effective pharmaceutical products.Reflecting the situation in the market, the overwhelming majority of these products are small molecules, with a small but notable portion of the pipeline consisting of other molecule types such as cell therapies, peptides and vaccines - none of which are currently present in the schizophrenia market.From the research finding included in the report "Frontier Pharma: Schizophrenia - Diverse First-in-Class Pipeline Shows Promise for Treatment of Negative and Cognitive Symptoms"; First-in-class products have the greatest potential in terms of development and commercial prospects. In line with the overall pipeline, first-in-class innovation is dominated by products acting on neuromodulator targets with the strongest representation in the Discovery and Preclinical stages of development.Scope- Innovation within schizophrenia is relatively small. What are the unmet needs across this therapy area?- There are 160 products in the pipeline for schizophrenia. What proportion of these products are first-in-class? How does first-in-class innovation vary by indication, development stage and molecular target class?- Although the first-in-class pipeline is small in comparison with other CNS-related disorders, it is relatively diverse, with numerous molecular targets. Which first-in-class targets have been identified as most promising for schizophrenia?- A total of 77 licensing deals and 44 development deals related to schizophrenia have been completed since 2006. Does schizophrenia attract high-value deals? Which first-in-class products have no prior deal involvement?Reasons to buy- Understand the current clinical and commercial landscape. This includes a comprehensive study of symptoms, epidemiology, etiology, pathophysiology, co-morbidities and complications, diagnosis and treatment options.- Visualize the composition of the schizophrenia market in terms of dominant molecule types and molecular targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the market.- Analyze the schizophrenia pipeline and stratify by stage of development, molecule type and molecular target.- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising first-in-class targets have been reviewed in greater detail.- Recognize commercial opportunities in the schizophrenia deals landscape by analyzing trends in licensing and co-development deals, and identifying schizophrenia therapies that have not yet been involved in deals, and that may provide potential investment opportunities.Read the full report: https://www.reportlinker.com/p05436785
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: [email protected]
US: (339)-368-6001 Intl: +1 339-368-6001
Advertisement
View original content:http://www.prnewswire.com/news-releases/frontier-pharma-schizophrenia---diverse-first-in-class-pipeline-shows-promise-for-treatment-of-negative-and-cognitive-symptoms-300759124.html
SOURCE Reportlinker
